Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

212 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

PsychedelicNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025

By: Investor Brand Network

June 18, 2025 at 11:45 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking place June 16-20, 2025, in Denver, Colorado. Psyence BioMed will present on business ethics in a panel session, “We are the Guardrails: Profit with Purpose.” In the role of Chief of Global Impact for Psyence Biomed, the first Nasdaq-listed biopharma with a focus on developing nature-derived (non-synthetic) psilocybin medicine for FDA approval, Gifford works in Washington, DC, to build bridges between research, regulation, and patient care.

To view the full press release, visit https://ibn.fm/qr93E

About Psyence Biomedical Ltd.

Psyence Biomed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. The name “Psyence” merges “psychedelics” and “science,” reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. For more information, visit the company’s website at www.PsyenceBiomed.com.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
Austin, Texas
www.PsychedelicNewsWire.com
512.354.7000 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	265.82	+0.00 (0.00%)
AAPL	294.80	+0.00 (0.00%)
AMD	448.29	+0.00 (0.00%)
BAC	50.78	+0.00 (0.00%)
GOOG	383.82	+0.00 (0.00%)
META	603.00	+0.00 (0.00%)
MSFT	407.77	+0.00 (0.00%)
NVDA	220.78	+0.00 (0.00%)
ORCL	186.83	+0.00 (0.00%)
TSLA	433.45	+0.00 (0.00%)